Brand dynamics
Group Real-Time Dynamics And Cutting-Edge Information In The Field Of One Health
Focus on making good new drugs | 2022 High-Quality Development Leading Enterprises and Leading Figures Selection Visits HealthGen
Published Time：
2022-09-30
On September 29, 2022, the selection of leading enterprises and leading figures in high-quality development in 2022 and the evaluation and research of the "Shenzhen Enterprise High-Quality Development Evaluation Index System (2022)" visited the participating enterprise Joincare Pharmaceutical Group Industry Co., Ltd.
Liu Xinran, Executive President and Secretary-General of Shenzhen Enterprise High-Quality Development Promotion Association; Li Xin, Director of the Technology Transfer Office of Harbin Institute of Technology (Shenzhen) and Executive Dean of Shenzhen Institute of High-Quality Development and New Structure; Wang Xu, Vice President of Shenzhen Huaxia Taihe Intellectual Property Co., Ltd.; Wu Jun, Director of Guangdong Siming Law Firm; and Li Min, President of Minsheng Bank Shenzhen Taian Branch, and other evaluation experts participated in the research and held talks with Jin Fang, Chief Scientist of Joincare Pharmaceutical Group Industry Co., Ltd., to understand the company's development history, product system, business layout, and brand building.
Company Profile
Joincare Pharmaceutical Group Industry Co., Ltd., established in 1992, is an innovative research and development-oriented comprehensive pharmaceutical company. Its business scope covers chemical preparations, traditional Chinese medicine preparations, chemical raw materials and intermediates, diagnostic reagents and equipment, health food, and other multiple fields. In 2021, the company achieved operating income of 15.904 billion yuan and invested 1.85 billion yuan in research and development. The company adheres to technological innovation as its strategic base point, insists on the dual-engine drive of innovative drugs and high-end complex preparations, continuously increases investment in research and development, pays attention to the cultivation and system construction of R&D personnel, owns multiple high-barrier complex preparation research and development platforms, and is in a leading position in the field of inhalation preparations.
Candidate for Leading Figure in High-Quality Development in 2022
Dr. Jin Fang, Chief Scientist of Joincare Pharmaceutical Group Industry Co., Ltd., Researcher, Doctoral Supervisor, National-level Selected Candidate of the New Century 10,000 Talents Program of the Ministry of Personnel, recipient of the State Council Special Allowance, member of the Ninth, Tenth, Eleventh, and Twelfth National Pharmacopoeia Committees, PI of the National Key Laboratory of Respiratory Diseases, member of the MCTOC of the United Nations Ozone Secretariat, and Shenzhen National-level Leading Talent; responsible for drafting various versions of the "Chinese Pharmacopoeia" inhalation preparation general rules and related determination methods, fully participating in the development and standard establishment process of China's inhalation preparations from scratch, and mastering the core key R&D and industrialization technologies of high-difficulty inhalation preparations.
For more than 30 years, Dr. Jin Fang has been working tirelessly on the front line of research and development of respiratory drugs and industrialization of high-end complex inhalation preparations. With his professional focus and pursuit of excellence, he has broken through the technological monopoly and "bottleneck" of a few multinational pharmaceutical companies internationally. Under his leadership, Jiankangyuan Group has carried out more than 40 inhalation preparation product R&D projects in 10 years, with 5 products and 9 specifications of inhalation preparation products launched, completing the first domestic consistency evaluation of inhalation preparations, and the first domestic inhalation antibiotic is about to be approved. To date, Jiankangyuan Group's inhalation preparation products have accumulated sales of nearly 1.5 billion yuan. Dr. Jin Fang is an outstanding leading figure in Jiankangyuan's establishment in Shenzhen, its move towards internationalization, its transformation and upgrading, and its innovation-driven development.
Dr. Jin Fang introduced that since the establishment of Jiankangyuan in 1992, it has always focused on the field of big health medicine and has gradually developed into a comprehensive pharmaceutical enterprise covering chemical preparations, traditional Chinese medicine preparations, chemical raw materials and intermediates, diagnostic reagents and equipment, and other multiple fields. Jiankangyuan advocates the coexistence of humanistic spirit and scientific research spirit, and undertakes the obligations and responsibilities of jointly building human health. While continuously developing itself, Jiankangyuan always remembers its mission and never forgets its original intention, practicing its mission of "For health, for tomorrow" in continuous inheritance and innovation.
With the progress of the times, behind the massive data of diseases is the scarcity of health resources, and the pharmaceutical industry is gradually entering a new cycle of innovation-driven development. For many years, Jiankangyuan Group has been committed to the interests of patients, taking the protection of human life and health as its core, and working with top domestic R&D teams to conduct in-depth research and strategic planning. As a practitioner of "Healthy China," it actively and continuously contributes to building a community with a shared future for mankind. In the future, Jiankangyuan will continue to adhere to the core values of "people-oriented, craftsmanship, innovation, and cooperation," paying attention to product quality, talent cultivation, and its own R&D strength, achieving the harmonious unity of the values of the enterprise and its employees, realizing the vision of "making good medicine and new medicine with heart," and showcasing the high spirits and strong potential of Chinese pharmaceutical enterprises to the world.
Hi, hello!
2022 Selection of Leading Enterprises and Leading Figures in High-Quality Development
Registration is in full swing
Please fill out the "Recommendation Form" and "Index System" quickly
On May 7, 2022, the selection of leading enterprises and leading figures in high-quality development in 2022 and the research activity of the "Shenzhen Enterprise High-Quality Development Evaluation Index System (2022)" were officially launched. The activity was guided by the Shenzhen Federation of Industry and Commerce (General Chamber of Commerce) and jointly organized by the Shenzhen Enterprise High-Quality Development Promotion Association and the Shenzhen Institute of High-Quality Development and New Structure of Harbin Institute of Technology (Shenzhen).
This year's event will adhere to the principles of objectivity, fairness, and authority. Through a series of work such as publicity and mobilization, field research, and expert review, it will invite enterprises with outstanding contributions and influence in promoting the comprehensive high-quality development of the economic and social development to participate in the evaluation of the "Shenzhen Enterprise High-Quality Development Evaluation Index System (2022)" and select 20 leading enterprises and 20 leading figures in high-quality development in 2022.
From "Shenzhen High-Quality Enterprise Association"
Quick Navigation
+86 755-33268688 | Service Hotline
Official WeChat Official Account
Copyright © 2025 Joincare Pharmaceutical Group Industry Co., Ltd. ALL Rights Reserve.